



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:54
Last Report Issued 02/02/2012 08:16

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1275B-POS
Patient ID 1275B-POS
Chain 12000240
Age Not Given DOB Not Given
Gender Not Given
Workorder 12000240
Received 02/02/2012 08:12

Sample ID 12000240-001
Matrix Blood
Patient Name 1275B-POS
Patient ID 1275B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

1275B Clonidine, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Clonidine 10 ng/mL 0.10 ELEVATED

Synonym(s): Catapres®; Duraclon; Kapvay®
Immediate-release, oral: 0.50 - 2.0 ng/mL, 2 hours
after administration
Sustained-release, patch: 0.20 - 2.0 ng/mL, at
steady-state
Sustained-release, oral: 0.20 - 0.27 ng/mL,
6.8 +/- 3.6 hours after a 0.1 mg single dose in
healthy fed adults;
children receive higher doses on a mg/kg basis.

The ratio of whole blood concentration to serum or
plasma concentration is unknown for this analyte.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US
Food and Drug Administration.